Clinical Trials Logo
  1. Home
  2. Chronic Kidney Disease
  3. NCT02808572
  4. Details
NCT02808572 Clinical Trial

New Biomarkers of Bone Mineral Metabolism as Cardiovascular Risk Factors in Chronic Kidney Disease Patients

Chronic Kidney Disease Clinical Trial

Official title:
New Biomarkers of Bone and Mineral Metabolism as Risk Factors for Morbidity/Mortality in Chronic Kidney Disease Patients Not Requiring Dialysis

Clinical Trial Details — Status: Recruiting

Administrative data
NCT number NCT02808572
Other study ID # UF9125
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date March 12, 2013
Est. completion date June 2031

Study information
Verified date December 2021
Source University Hospital, Montpellier
Contact Jean-Paul CRISTOL, Prof
Phone +33(0)4 67 33 83 15
Email jp-cristol@chu-montpellier.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To evaluate the relationships between bone mineral metabolism markers (osteoprotegerin, fibroblast growth factor 23) at inclusion and the occurence of cardiovascular events during a 7 year follow-up.

Recruitment information / eligibility
Status Recruiting
Enrollment 250
Est. completion date June 2031
Est. primary completion date March 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 95 Years
Eligibility Inclusion Criteria: - Patient who has signed the written consent form - Patient with chronic renal failure defined by glomerular filtration rate (GFR) but without dialysis therapy Exclusion Criteria: - Pregnancy - Patient with chronic renal failure requiring dialysis therapy

Study Design

Related Conditions & MeSH terms

Intervention

Biological:
• Plasma osteoprotegerin level
dosage of plasma osteoprotegerin
• Plasma fibroblast growth factor 23 level
dosage of plasma fibroblast growth factor 23
Procedure:
• Vascular calcification score
measurement of vascular calcification score by multidetection computerized tomography

Locations
Country Name City State
France AIDER Montpellier
France CHU Montpellier, Cardiology department Montpellier
France CHU Montpellier, Endocrinology department Montpellier
France CHU Montpellier, Intensive care unit Montpellier
France CHU Montpellier, Internal medicine department Montpellier
France CHU Montpellier, Nephrology department Montpellier
France AIDER Saint-Jean-de-Védas

Sponsors (1)
Lead Sponsor Collaborator
University Hospital, Montpellier

Country where clinical trial is conducted

France, 

Outcome
Type Measure Description Time frame Safety issue
Primary Occurence of at least one cardiovascular event during the 7 year follow-up according to osteoprotegerin level at inclusion osteoprotegerin will be measured in picomol/L 7 years after inclusion
Secondary Occurence of at least one cardiovascular event during the 7 year follow-up according to fibroblast growth factor 23 level at inclusion fibroblast growth factor 23 will be measured in RU/milliliter 7 years after inclusion
Secondary Occurence of at least one cardiovascular event during the 7 year follow-up according to vascular calcification score at inclusion 7 years after inclusion
Secondary Mortality 7 years after inclusion
Secondary Kidney functions values of creatinine during the 7 year follow-up
See also
  Status Clinical Trial Phase
Completed NCT05491642 - A Study in Male and Female Participants (After Menopause) With Mild to Moderate High Blood Pressure to Learn How Safe the Study Treatment BAY3283142 is, How it Affects the Body and How it Moves Into, Through and Out of the Body After Taking Single and Multiple Doses Phase 1
Recruiting NCT06363097 - Urinary Uromodulin, Dietary Sodium Intake and Ambulatory Blood Pressure in Patients With Chronic Kidney Disease
Terminated NCT04043026 - The Effects of Renal Function and Atrial Fibrillation on Lipoproteins and Clot Structure/Function
Completed NCT05318014 - Low-protein Formula Supplements in Chronic Kidney Disease N/A
Active, not recruiting NCT06071065 - Clinical Pharmacist Intervention on Medication Adherence and Clinical Outcomes in Chronic Kidney Disease Patients N/A
Completed NCT02878317 - Skin Autofluorescence as a Risk Marker in People Receiving Dialysis.
Not yet recruiting NCT06039254 - Safety and Pharmacokinetics of HRS-1780 in Healthy Subjects and Subjects With Impaired Renal Function Phase 1
Recruiting NCT03160326 - The QUALITY Vets Project: Muscle Quality and Kidney Disease
Completed NCT02836574 - A Study of Renal Autologous Cell Therapy (REACT) in Type 2 Diabetics With Chronic Kidney Disease Phase 2
Completed NCT02888171 - Impact of Ferric Citrate vs Ferrous Sulfate on Iron Parameters and Hemoglobin in Individuals With CKD and Iron Deficiency N/A
Completed NCT02756520 - Observational Study on CKD Treatment With a Ketosteril Supplemented Protein-restricted Diet (Keto-024-CNI)
Completed NCT02875886 - DD-study: Diet or Diuretics for Salt-sensitivity in Chronic Kidney Disease Phase 4
Withdrawn NCT02885545 - The Strategy to Prevent Hemorrhage Associated With Anticoagulation in Renal Disease Management (STOP HARM) Trial Phase 4
Completed NCT02896309 - The Effect of Correction of Metabolic Acidosis in CKD on Intrarenal RAS Activity N/A
Active, not recruiting NCT02483039 - Nephrologist Follow-up Versus Usual Care After an Acute Kidney Injury Hospitalization N/A
Completed NCT02992548 - Effect of Pravastatin on Erythrocyte Membrane Fatty Acid Contents in Patients With Chronic Kidney Disease Phase 4
Completed NCT02369549 - Micro-Particle Curcumin for the Treatment of Chronic Kidney Disease Phase 3
Terminated NCT02543177 - Optimised Procedure in Patients With NSTEMI and CKD N/A
Recruiting NCT02205944 - Impact of Presurgical Exercise on Hemodialysis Fistula Outcomes N/A
Active, not recruiting NCT02231138 - Efficacy and Safety of Abelmoschus Manihot for Chronic Kidney Disease Phase 4